Objective:To study and compare the clinical effects of the combination of different interventional embolization chemotherapy and radiofrequency ablation in patients with primary liver cancer.Methods:In this paper,base...Objective:To study and compare the clinical effects of the combination of different interventional embolization chemotherapy and radiofrequency ablation in patients with primary liver cancer.Methods:In this paper,based on the target data validation of those 60 patients with primary liver cancer treated in the hospital during the period from May 2017 to May 2018,the double-blind method was used for the comparison between groups.Patients in the reference group were treated with the combination of cisplatinum interventional chemoembolization regimen and radiofrequency ablation,while those in the experimental group were treated with the combination of lobaplatin interventional chemoembolization regimen and radiofrequency ablation.Then,the efficacy of both groups was compared.Results:After the treatment,the clinically effective total value,the calculation value of adverse reactions,and the value of IgA,IgM,IgG and AFP of the experimental group were compared with those of the reference group.In addition,the value of IgA,IgM,IgG and AFP of both groups after and before the treatment were compared.The experimental results showed that the data was statistically significant(P<0.05).Conclusion:The combination of lobaplatin and cisplatin interventional embolization chemotherapy and radiofrequency ablation has some effects in patients with primary liver cancer,but the former one showed more significant effects.展开更多
Objective: To probe the relationship between survival period and immune function of hepatic carcinoma patients after embolization chemotherapy. Methods: One hundred and eight patients of hepatocarcinoma were randomly ...Objective: To probe the relationship between survival period and immune function of hepatic carcinoma patients after embolization chemotherapy. Methods: One hundred and eight patients of hepatocarcinoma were randomly divided into three groups. Group A was treated by embolization chemotherapy (ECT) alone, immunotherapy and Chinese herbal medicine were given to Group B and C respectively after ECT. Results: The short-term effective rate of Group A, B and C was 61. 1 %, 83. 3 % and 80. 6% respectively, the three-year survival rate 28. 6 %, 39. 1 % and 47. 3 %, and the median survival time 11 months, 17 months and 15 months respectively. Observation on immune function after treatment showed that patients who received ECT alone had a lower immunity while those who received immunotherapy or Chinese herbal medicine had a strengthened immunity. Conclusion: Survival period of hepatocarcinoma patients is related with their immune function, strengthening patients' immunity could extend their survival period relatively.展开更多
文摘Objective:To study and compare the clinical effects of the combination of different interventional embolization chemotherapy and radiofrequency ablation in patients with primary liver cancer.Methods:In this paper,based on the target data validation of those 60 patients with primary liver cancer treated in the hospital during the period from May 2017 to May 2018,the double-blind method was used for the comparison between groups.Patients in the reference group were treated with the combination of cisplatinum interventional chemoembolization regimen and radiofrequency ablation,while those in the experimental group were treated with the combination of lobaplatin interventional chemoembolization regimen and radiofrequency ablation.Then,the efficacy of both groups was compared.Results:After the treatment,the clinically effective total value,the calculation value of adverse reactions,and the value of IgA,IgM,IgG and AFP of the experimental group were compared with those of the reference group.In addition,the value of IgA,IgM,IgG and AFP of both groups after and before the treatment were compared.The experimental results showed that the data was statistically significant(P<0.05).Conclusion:The combination of lobaplatin and cisplatin interventional embolization chemotherapy and radiofrequency ablation has some effects in patients with primary liver cancer,but the former one showed more significant effects.
文摘Objective: To probe the relationship between survival period and immune function of hepatic carcinoma patients after embolization chemotherapy. Methods: One hundred and eight patients of hepatocarcinoma were randomly divided into three groups. Group A was treated by embolization chemotherapy (ECT) alone, immunotherapy and Chinese herbal medicine were given to Group B and C respectively after ECT. Results: The short-term effective rate of Group A, B and C was 61. 1 %, 83. 3 % and 80. 6% respectively, the three-year survival rate 28. 6 %, 39. 1 % and 47. 3 %, and the median survival time 11 months, 17 months and 15 months respectively. Observation on immune function after treatment showed that patients who received ECT alone had a lower immunity while those who received immunotherapy or Chinese herbal medicine had a strengthened immunity. Conclusion: Survival period of hepatocarcinoma patients is related with their immune function, strengthening patients' immunity could extend their survival period relatively.
